These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19954314)

  • 1. Personalized antiplatelet therapy for coronary artery disease patients: is this the future?
    Bonello L; Lemesle G; De Labriolle A; Barragan P; Camoin-Jau L; Paganelli F
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1525-32. PubMed ID: 19954314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonresponders to clopidogrel therapy among Indian patients undergoing elective/adhoc angioplasty.
    Thomson VS; John B; Pati PK; George OK; George PV; Jose J
    Indian Heart J; 2008; 60(6):543-7. PubMed ID: 19276493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.
    Abuzahra M; Pillai M; Caldera A; Hartley WB; Gonzalez R; Bobek J; Dokainish H; Lakkis N
    Am J Cardiol; 2008 Aug; 102(4):401-3. PubMed ID: 18678295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of clopidogrel resistance.
    De Miguel A; Ibanez B; Badimón JJ
    Thromb Haemost; 2008 Aug; 100(2):196-203. PubMed ID: 18690337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
    Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
    J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy.
    Cesari F; Marcucci R; Caporale R; Paniccia R; Romano E; Gensini GF; Abbate R; Gori AM
    Thromb Haemost; 2008 May; 99(5):930-5. PubMed ID: 18449424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
    Bhatt DL
    Am J Cardiol; 2009 Feb; 103(3 Suppl):11A-19A. PubMed ID: 19166708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of the concept of platelet reactivity monitoring of response to thienopyridines.
    Bonello L; De Labriolle A; Scheinowitz M; Lemesle G; Roy P; Steinberg DH; Pinto Slottow TL; Pakala R; Pichard AD; Barragan P; Camoin-Jau L; Dignat-George F; Paganelli F; Waksman R
    Heart; 2009 Aug; 95(15):1214-9. PubMed ID: 19196732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
    Siller-Matula JM; Lang I; Christ G; Jilma B
    J Am Coll Cardiol; 2008 Nov; 52(19):1557-63. PubMed ID: 19007592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.
    Antonino MJ; Jeong YH; Tantry US; Bliden KP; Gurbel PA
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1011-22. PubMed ID: 23030291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
    Lepäntalo A; Virtanen KS; Heikkilä J; Wartiovaara U; Lassila R
    Eur Heart J; 2004 Mar; 25(6):476-83. PubMed ID: 15039127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.